IDT Australia announces board shake-up
CMO IDT Australia (ASX:IDT) has announced a board reshuffle to support a planned expansion drive.
The company revealed that Alan Blackman and Robert Burnet - both of whom have been serving on the board for 27 years - will step down as directors at the end of June.
Reo Shigeno, CEO of Japanese clinical trial site management company I’rom Holdings’ Australian subsidiary, will join the board as a non-executive director. I’rom Holdings this month acquired an 18.8% stake in IDT Australia for $2 million in shares.
Also joining the board will be Australian biotechnology veteran Graeme Kaufman. A long-time former CSL executive, Kaufman is currently chairman of Bionomics (ASX:BNO) and a director at Cellmid (ASX:CMD).
IDT chairman and founder Dr Graeme Blackman will meanwhile step aside from the role during calendar Q3. A replacement will be selected in the interim.
The board shake-up comes one month after IDT appointed Dr Paul MacLeman as its new CEO. Prior to joining IDT Australia, MacLeman was most recently CEO of Genetic Technologies (ASX:GTG).
IDT Australia shares were trading unchanged at $0.25 as of around 1 pm on Thursday.
Link between oestrogen and heart health found in women
Scientists found that oestrogen helps increase the ANXA1 protein, and when ANXA1 is missing, the...
Frequent nightmares accelerate aging, increase risk of death
Nghtmares independently predict faster biological aging and earlier mortality — even after...
Cardiac organoids bring hope for treating heart disease
Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...
